BC Week In Review | Aug 10, 2018
Clinical News

Spring Bank details peak HBV DNA and HBV RNA reductions for 100 mg dose of inarigivir

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 patients in the third cohort of Part A of Phase II ACHIEVE trial to treat chronic HBV infection showing that 100 mg inarigivir soproxil led to...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BioCentury | Dec 2, 2017
Strategy

Opening the gates in China

A flurry of approvals of HCV drugs in China this year illustrates how the country’s regulatory reforms have leveled the playing field for multinational drug sponsors, who had been disadvantaged compared with domestic companies. As...
BC Week In Review | Oct 27, 2017
Clinical News

Replicor HBV combo leads to functional control

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat non-cirrhotic, hepatitis B e antigen (HBeAg)-negative, chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir...
BC Week In Review | Oct 27, 2017
Clinical News

Spring Bank reports Phase II data for HBV candidate

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 treatment-naive patients with chronic HBV infection without cirrhosis in the first cohort of the Phase II ACHIEVE trial showing that once-daily 25 mg inarigivir soproxil (formerly...
BC Extra | Oct 23, 2017
Clinical News

Replicor HBV combo leads to functional control

Replicor Inc. (Montreal, Quebec) reported interim data from the Moldovan Phase II REP 401 trial to treat chronic HBV infection showing that REP 2139-Mg in combination with Viread tenofovir disoproxil fumarate and Pegasys peginterferon alfa-2a...
BioCentury | Sep 9, 2017
Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
BC Week In Review | Jul 21, 2017
Company News

Spring Bank and Gilead combo trial to treat chronic HBV

Gilead Sciences Inc. (NASDAQ:GILD) will fund and conduct a Phase II evaluating its HBV drug Vemlidy tenofovir alafenamide fumarate plus SB 9200 from Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) in patients with chronic HBV infection. Spring...
BC Week In Review | May 26, 2017
Clinical News

DSMB recommends continuation of Phase II for SB 9200 in HBV

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) said an independent DSMB recommended continuation of the Phase II ACHIEVE trial evaluating SB 9200 in treatment-naïve HBV patients without cirrhosis. The company has begun enrollment in the second cohort...
Items per page:
1 - 10 of 424